Literature DB >> 3470556

HTLV-III antibody prevalence among young delinquent drug abusers in long-term residential treatment at a North-German drug clinic.

G Paschelke, G Altvater-Kremer, W D Meyer, H Kremer.   

Abstract

To date, long-term intravenous drug users studied at regional European centers of illicit drug use have had a high number of LAV/HTLV-III infections. Among 200 patients remanded by court or referred from prison to a special clinic in northern Germany for young delinquent drug abusers, 26 (17%) of 157 IV drug abusers were HTLV-III seropositive. With 40% seropositive, female patients showed a significantly higher prevalence of HTLV-III infection than males. The results of longitudinal serological, immunological, and clinical observations over periods of 12 months and 2-3 years indicate that under conditions of continuous medical surveillance, sound preventive counseling, and steady therapeutic care during long-term coeducative residential treatment of drug abusers, neither detectable HTLV-III transmission nor definite progression of HTLV-III induced impairment of immune regulatory functions must ensue.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470556     DOI: 10.1007/BF01785522

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany.

Authors:  G Hunsmann; J Schneider; H Bayer; R Kurth; A Werner; H D Brede; V Erfle; W Mellert; H R Brodt; L Bergmann
Journal:  Klin Wochenschr       Date:  1985-03-01

2.  HTLV-III antibody in Edinburgh drug addicts.

Authors:  J F Peutherer; E Edmond; P Simmonds; J D Dickson; G E Bath
Journal:  Lancet       Date:  1985-11-16       Impact factor: 79.321

3.  High frequency of HTLV-III antibodies among heterosexual intravenous drug abusers in the Austrian Tyrol.

Authors:  D Fuchs; H G Blecha; F Deinhardt; M P Dierich; F D Goebel; P Hengster; H Hinterhuber; D Schoenitzer; K Traill; H Wachter
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

4.  HTLV-III antibody among Italian drug addicts.

Authors:  P Ferroni; D Geroldi; C Galli; A R Zanetti; A Cargnel
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

5.  Rapid spread of HTLV-III infection among drug addicts in Italy.

Authors:  G Angarano; G Pastore; L Monno; T Santantonio; N Luchena; O Schiraldi
Journal:  Lancet       Date:  1985-12-07       Impact factor: 79.321

6.  HTLV-III antibody in Swiss and English intravenous drug abusers.

Authors:  P P Mortimer; E M Vandervelde; W J Jesson; M S Pereira; F Burkhardt
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

7.  Intravenous drug users and the acquired immune deficiency syndrome.

Authors:  H M Ginzburg
Journal:  Public Health Rep       Date:  1984 Mar-Apr       Impact factor: 2.792

8.  [Viral hepatitis and AIDS-associated HTLV III/LAV virus infections in drug addicts].

Authors:  H I Joller-Jemelka; U Wilhelm; R Steffen; P J Grob
Journal:  Schweiz Med Wochenschr       Date:  1985-08-17

9.  The epidemiology of AIDS: current status and future prospects.

Authors:  J W Curran; W M Morgan; A M Hardy; H W Jaffe; W W Darrow; W R Dowdle
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

10.  [Prevalence of antibodies against HTLV-III in various regions in Switzerland].

Authors:  J Schüpbach; M Vogt; R Bhushan; R Lüthy; O Haller; H Joller; T Ferber; S Büchner; R Schuppli; J Schädelin
Journal:  Schweiz Med Wochenschr       Date:  1985-07-27
View more
  1 in total

1.  HIV infection in intravenous drug abusers in Berlin: risk factors and time trends.

Authors:  K Stark; R Müller; I Guggenmoos-Holzmann; S Deininger; E Meyer; U Bienzle
Journal:  Klin Wochenschr       Date:  1990-04-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.